Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Colorcon
AstraZeneca
Johnson and Johnson
Medtronic

Last Updated: February 16, 2020

DrugPatentWatch Database Preview

Litigation Details for Valeant International, Bermuda v. Watson Pharmaceuticals Inc. (S.D. Fla. 2010)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Valeant International, Bermuda v. Watson Pharmaceuticals Inc. (S.D. Fla. 2010)

Docket   Start Trial Date Filed 2010-02-19
Court District Court, S.D. Florida Date Terminated 2011-11-07
Cause 35:0271 Patent Infringement Assigned To Federico A. Moreno
Jury Demand None Referred To Magistrate Judge Stephen T. Br
Parties BIOVAIL LABORATORIES INTERNATIONAL SRL; VALEANT INTERNATIONAL (BARBADOS) SRL; VALEANT INTERNATIONAL, BERMUDA; WATSON LABORATORIES, INC. - FLORIDA; WATSON PHARMA, INC.; WATSON PHARMACEUTICALS INC.
Patents 3,819,706; 4,536,518; 5,358,970; 5,427,798; 5,532,415; 5,874,447; 6,110,940; 6,143,327; 7,241,805; 7,569,610; 7,572,935; 7,598,271; 7,649,019
Attorneys Clinton H. Brannon; Darcy L. Jones; Gail Ann McQuilkin; Georgianna Witt Braden; Harley Shepard Tropin; Janet T. Munn; Jeffrey J. Toney; John L. North; Matthew F. Greinert; Meghan M. Rachford; Michael P. Padden; Norman E. B. Minnear; Theresa M. Gillis; Thomas W. Jenkins
Firms Howrey LLP; Mayer Brown LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Valeant International, Bermuda v. Watson Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Valeant International, Bermuda v. Watson Pharmaceuticals Inc. (S.D. Fla. 2010)

Date Filed Document No. Description Snippet Link To Document
2011-06-21 115 R PE 088 7/2/1996 U.S. Patent No. 5,532,415 BIOVAIL-WAT743510-743550… Notes re repeating example 1 of '706 patent LA … Notes re repeating example 1 of '706 patent LA … 71) PE 073 U.S. Patent Prosecution History File BIOVAIL-WAT741191… Information PE 080 2/8/2011 U.S. Patent No. 7,884,136 B2 External link to document
2011-07-29 140 Depo Ex. 003] DE 135 U.S. Patent No. 3,819,706 to Mehta [Adlington Depo Ex. 03; Buckton… Silversone DE 557 U.S. Patent No. 3,819,706 DE 565 Notice of Deposition…from U.S. Patent File History No. 7,241,805 DE 013 Excerpts from U.S. Patent File History…from U.S. Patent File History No. 7,569,610 DE 015 Excerpts from U.S. Patent File History…from U.S. Patent File History No. 7,649,019 DE 017 Excerpts from U.S. Patent File History External link to document
2011-11-07 155 subsequently patented by Mehta in 1974 in U.S.PatentNo.3,819.706 (the tkM ehta patent'').(Def.Ex…ingredient. Valeant owns four patents related to Aplenzinl : U.S. Patent Nos. 7,569,610, 7,563,823,…$610 patent;(2)Claim 9 ofthe:823patent;(3)Claim 10ofthe $823patent;(4)Claim 2 ofthe 1019 patent, …Moreover,whenthe Patent O ffice has considered the prior art during prosecution of the patents,the burden on…contends that Claim 3 of the $610 patent and Claim l of the 1992 patent are invalid foranticipationunder35U.S.C.j External link to document
2011-11-08 158 and was subsequently patented by M ehta in 1974 in (J.S.PatentNo.3,819,706 (the SkMehta patenf'…ingredient. V aleant ow ns four patents rclated to A plenzin* : U .S. Patent N os. 7,569,610, 7,563,823,7,649,019…betweentheparties.Therepresentativeclaimsofthepatents-in-suitare:(1)Claim 3ofthe1610 patent;(2)Claim 9 ofthe$823 patent' … ,(3)Claim 10 ofthe;823 patent;(4)Claim 2 ofthe$019 patent;and (5)Claim 1ofthe1992patent.Thcrepresentativeclaimsrelatetocontrolledrelease… tabletcovered by the patents-in-suit. The effective filing date ofthe patents-in-suitis June 27,2005 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
McKesson
Moodys
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.